by Peter Ciszewski | Aug 20, 2020
Aviva Rosenberg of the Gaucher Community Alliance discusses some of the projects her organization is doing to assist the Gaucher disease community during the COVID-19 pandemic. This presentation was part the live GRIDS 2020-Virtual Summit held July 1, 2020 and...
by Peter Ciszewski | Aug 19, 2020
Jennifer Elliott, PhD, Global Project Leader at Takeda Oncology, discusses the symptoms commonly associated with myelodysplastic/myeloproliferative syndromes (MDS). Myelodysplastic/myeloproliferative syndromes, as defined by the NIH, are a group of diseases of...
by Peter Ciszewski | Aug 17, 2020
Courtney Dinardo, MD from MD Anderson Cancer Center discusses how the COVID-19 pandemic has affected rare disease patients, particularly in acute myeloid leukemia (AML) patients. AML is an aggressive cancer of the blood and bone marrow with a 5-year survival...
by Peter Ciszewski | Aug 17, 2020
Renuka Limgala, PhD, of the Lysosomal & Rare Disorders Research & Treatment Center (LDRTC) explains the immunopathogenesis of lysosomal disorders and how that may play a presumptive role in SARS-CoV-2 severity. This presentation was part the GRIDS...
by Peter Ciszewski | Aug 14, 2020
Mikkael Sekeres, MD from the Sylvester Comprehensive Cancer Center discusses data from a phase II study comparing pevonedistat plus azacitidine vs azacitidine alone in higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML), or...
